Raise Closing Soon
00 DAYS
:
00 HOURS
:
00 MIN
:
20 SECS
Restoring Vision with Breakthrough Smart Glasses
Join the forefront of the smart glasses revolution with Innovega, delivering quality of life and independence to 295 million with vision impairment, while building a versatile AR platform for defense, enterprise, sports, and beyond.
  • Backed by Tencent, Vuzix, Vispero, and strategic partners
  • 75+ filed patents protecting our nano-optic technology
  • $6M+ U.S. government contracts with Defense Advanced Research Projects Agency (DARPA)
  • 700+ individuals on early product reservation list. 
Targeted launch in 2026.
Share in our growth. Invest in Innovega.
I'm Ready to Invest
This Reg CF offering is made available through StartEngine Primary LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
$XXX,XXX.XX RAISED SO FAR
This video includes forward-looking and promotional statements. Descriptions of vision improvement and user experience reflect intended design and individual experiences during demonstrations or testing and are not guaranteed. Results may vary.
Capital Raised
$22,000,000+
(including $7M+ from crowdfunding)
Investors
3,000+
Share Price
$3
Min. Investment
$498
Top Reasons to Invest
‍
Developing best-in-class technology
Clinically Proven Breakthrough
‍
Clinically Proven Breakthrough
Independent testing at Ohio State University achieved average 20/20 functional vision for legally blind participants
Massive, Growing Market
‍
295 million with moderate to severe vision loss worldwide, projected to 500 million by 2050
Dual Launch Path
‍
Gen I Smart Glasses (glasses-only, planned 2026 launch) for moderate impairment; Gen II (glasses + nano-optic contacts, targeted 2027/2028) for severe/legal blindness, plus AI platform for enterprise, defense, sports.
These results are based on early-stage clinical testing. Reported functional vision outcomes reflect performance while using Innovega’s investigational system. Results may vary. Innovega’s contact lenses are investigational and not yet approved by the FDA.
Trusted by Global Leaders
Tencent led a $3M early investment round in Innovega as a global tech giant and parent of WeChat, with deep expertise in AI, gaming, and consumer platforms. Their backing provides strategic access to massive Asian markets and accelerates commercialization of our vision tech.
A leading innovator in AR and smart glasses, has provided strategic investment and collaboration to Innovega. This partnership strengthens our hardware expertise and positions us for expanded enterprise, consumer, and AR market opportunities.
A pioneer in accessibility software for the visually impaired, supports Innovega through strategic connections and backing. Their expertise in low-vision tools aligns perfectly with our mission to restore independence for millions, accelerating market entry into the assistive technology sector.
Awarded Innovega multiple contracts as part of over $6M in non-dilutive government funding. These high-profile validations demonstrate our technology's proven reliability for demanding, high-performance applications and unlock significant potential for defense licensing and enterprise partnerships.
The problem
Millions with Low Vision Face Daily Barriers
Struggling to read a medicine label, spot a loved one's face across the room, or walk confidently without fear. Today's options including handheld magnifiers, bulky VR-style headsets, heavy goggles, or white canes feel outdated, uncomfortable, socially isolating, and limit real-life use.
The Solution
Innovega Changes Everything
Our lightweight, stylish smart glasses deliver real-world vision restoration. With high-res cameras, customizable displays, real-time control, and personalized zoom/AI enhancements, we project sharp imagery directly into your field of view. You can wear them all day like regular eyewear. This means faster, more natural vision enhancement at a fraction of the bulk and discomfort of legacy solutions.
  • GEN I Smart Glasses (Targeted Launch 2026) - Our glasses-only design with high-resolution cameras and customizable displays.
  • GEN II Smart Glasses + Contacts (Targeted Launch 2028) - Smart glasses paired with our patent protected nano-optic contact lenses, delivering full-field, functional vision.
Functional vision restoration refers to performance achieved while using Innovega’s smart glasses, and where applicable, in combination with its investigational nano-optic contact lenses. Results may vary by individual and condition. Innovega’s nano-optic contact lenses are investigational and not FDA approved.
market
Vision Impairment is a Global Crisis Poised for Growth
Over 1.1 billion people worldwide live with some form of vision loss today, including 295 million with moderate to severe impairment (the core target for our discreet, wearable solutions). We’re entering this pivotal moment with patented, clinically validated technology, ready to define a new category of discreet, all-day wearable vision restoration for millions who have never had real options.
Quoted statements reflect general views on augmented reality and smart glasses and do not refer to or endorse Innovega or its eyewear, which is designed for vision assistance.
I'm Ready to Invest
Aging Population Driving Massive Surge 
in Target Market
‍‍Driven by global aging (people over 65 nearly doubling by 2050) and lifestyle factors (rising diabetes, obesity, myopia in younger populations), moderate to severe vision impairment is expected to reach 474 million by 2050.

‍
Massive Untapped Spending Potential
‍‍In the US alone, 20 million affected individuals spend an average $16,838 annually on limited aids, creating significant opportunity for scalable, next-gen solutions like Innovega's platform.
‍
Source. Projections shown are based on third-party forecasts and are subject to change. They are not guarantees of future outcomes.
Thank you for signing up to receive Innovega Updates!
Oops! Something went wrong while submitting the form.
By clicking "Learn More", you consent to receive marketing communications including text messages and emails (e.g., promotions, cart reminders, funding updates) from StartEngine Crowdfunding, Inc. using the contact information you provide. You understand and agree that messages may be sent using an autodialer or automated systems. Consent is not a condition of purchase. Message and data rates may apply; message frequency varies. You may unsubscribe from email communications at any time by clicking the unsubscribe link in the email, and from text messages by replying STOP. For more information, see our Privacy Policy & Terms.

“The future is smart glasses.”
Mark Zuckerberg, Meta CEO
"I believe that augmented reality is the next big thing, and it will pervade all of our lives."
Tim Cook, Apple CEO
“We are restoring independence and clarity to a massive vision impairment crisis, positioning Innovega at the forefront of a $572B+ medical devices market.”
Steve Willey, Innovega CEO
Low Vision User Testimonials
Isaac
Juvenile Retinochosis
“I’ve always dreamt of the day I could see clearly, even if just enough to recognize faces. This past weekend, that dream became a reality with the help of Innovega’s technology.”
Kym
Ocular Albinism
“I didn't think that there was going to be anything that could help me see, and the fact that I was able to read the small print...that alone is mind-blowing to me. It's giving me chills.”
Megan
Stargardt Disease
“When I put them on, I felt like I was in a movie theatre. I could see everybody’s faces and I can’t normally do that. It’s a special thing.”
Paul
Macular Degeneration
“Six months ago I quit driving. With these glasses, I could drive! I don’t know how they did it? I could see like I haven’t see in a long time.”
These testimonials reflect individual experiences during demonstrations or testing and may not be representative of all users. Statements regarding vision improvement are not guaranteed and results may vary. References to driving or other regulated activities do not imply restored legal ability to perform such activities.
Read the Independent 
Clinical Evaluation
Imagine a legally blind person seeing their grandchild's face clearly for the first time, or reading without struggle. Independent testing by Ohio State University, presented at ARVO (Association for Research in Vision and Ophthalmology), showed our system delivers exactly that: average functional vision improved to ~20/20 for participants with severe low vision, unlocking greater independence for millions who have previously never had solutions available to them.
Download the ARVO Abstract
Thank you for signing up to receive Pytheas Energy Updates!
Oops! Something went wrong while submitting the form.
By clicking "Download", you consent to receive marketing text messages (e.g. promos, cart reminders) from StartEngine Crowdfunding, Inc. at the number provided, including messages sent by autodialer. Consent is not a condition of purchase. Msg & data rates may apply. Msg frequency varies. Unsubscribe at any time by replying STOP or clicking the unsubscribe link (where available). Privacy Policy & Terms

This study reports results from a small, single-visit feasibility study conducted in a controlled research setting. Visual acuity outcomes reflect performance during testing and may not be representative of all users or real-world use. The study does not imply FDA approval or clearance.
Business model
Multiple Revenue Streams
Our platform starts with vision restoration for the visually impaired but expands into high-growth AR applications through licensing and partnerships (defense, public safety, sports, gaming, enterprise).
1
Hardware sales
Innovega plans to generate revenue from direct and indirect sales of our smart glasses, with potential financing options to make them accessible, targeting both individual consumers and resellers for scalable hardware distribution.
2
Institutional Sales / 
Insurance Reimbursement
Innovega plans to sell our smart glasses and lenses through institutional channels (e.g., VA hospitals) and secure potential reimbursements from insurers like VSP, leveraging medical coding for low-vision aids to drive high-volume adoption in healthcare.
3
Recurring Subscription Sales (Vision-as-a-Service)
We intend to offer Vision-as-a-Service subscriptions for recurring revenue, including monthly AI upgrades, cloud-connected features, and replacement nano-optic contact lenses, providing ongoing value and predictable income from users.
4
Application Expansion 
Via Partner Licensing
We aim to license our patented IP and glasses tech to partners in defense, public safety, sports, gaming, and enterprise, opening new markets with royalties and collaborations that expand beyond vision impairment into broader AR applications.
Our Roadmap to
Commercialization
We’ve already secured strategic partners, completed breakthrough technology development, and validated our impact through independent clinical studies. Now, we’re testing low vision patients in our lab, and transitioning into full-scale commercial production. This is your opportunity to join us at a key phase in our growth.
Statements regarding vision improvement reflect individual experiences during testing and are not guaranteed. Results may vary. References to future availability or timelines are targets and subject to change.
I'm Ready to Invest
2008
Innovega Founded
‍
Company is incorporated in Washington by CEO Steve Willey and optometrist Dr. Jerome Legerton, with a focus on patented nano-optic contact lenses and smart glasses for extended field of view AR/VR.
2009
Initial IP Development
‍
Innovega begins filing patents in nano-optics and display systems, laying the foundation for 14 IP families and over 75 domestic/international patents spanning contact lens fabrication, micro-displays, and vision enhancement.
2011
Leadership Solidified
‍
Steve Willey assumes CEO role, bringing experience from multiple successful exits (including NASDAQ listings at MicroVision and Lumera) to guide development of the eMacula/iOptik platform.
2012
Early Prototype
‍
Innovega demonstrates initial contact lens + glasses system at CES, attracting attention for its potential in augmented reality and drawing early contracts from U.S. government agencies.
2014-2017
Non-Dilutive Government Funding
Secures $6M+ in contracts from DARPA, U.S. Army, NIH, NSF, Microsoft, and Oakley, funding R&D for high-performance optics, AR prototypes, and initial vision impairment applications.
2018
Patent Allowances Issued
‍
U.S. Patent Office issues multiple allowances, complementing 11 existing U.S. patents and strengthening Innovega's portfolio in wearable displays and nano-tech lenses.
2019
Initial Clinical Testing at OSU
‍
Conducts early human subject trials at Ohio State University College of Optometry, demonstrating functional vision improvements for low-vision participants, including legally blind individuals.
2021
ARVO Clinical Results Published
‍
Presents independent Ohio State study at ARVO, showing average functional vision improved to ~20/20 for severe low-vision participants; files additional patents for automated fitting systems.
2022
First Commercial License
‍
Signs licensing agreement with Vispero (global supplier of aids for visually impaired), marking the first commercial deal for the eMacula system; raises $5.6M in Reg A crowdfunding on SeedInvest.
2022
Total Funding Hits $16M
‍
Closes additional rounds, reaching $16M in total capital from institutional, strategic, and crowd investors; expands team to 20+ for clinical and manufacturing prep.
2023
Phase I/II FDA Trials Completed
‍
Successfully completes Phase I and II human subject testing for nano-optic contact lenses, optimizing design for safety and efficacy; begins Phase III preparation.
2024
Crowdfunding Milestone
‍
Raises additional funds on StartEngine, surpassing $20M total and engaging 2,800+ investors; secures joint development agreements with trade partners.
2025
Prototypes Finalized & Reservations Surge
Completes full-function prototypes for Gen I Founders Series; builds early product reservation list to 700+; hires key team like CTO Dr. Arthur Zhang (ex-Apple Vision Pro architect).
2026
Gen I Founders Series Launch
‍
Launch lightweight, glasses-only smart glasses
2027/2028
Gen II Commercial Rollout
‍
· Pair glasses with FDA-approved nano-optic contacts for severe/legal blindness
· Begin insurance reimbursements and institutional sales (e.g., VA hospitals)
· Expand licensing to defense, public safety, sports, and gaming partners
2028+
Full-Scale Expansion & Application Growth
· Ramp AI integrations and cloud upgrades for Vision-as-a-Service subscriptions
· 1M+ units annually across medical, enterprise, and consumer markets
· License IP for broader AR/VR ecosystems
· Enter global partnerships for multi-billion revenue streams in vision care and wearables
Invest Now
to accelerate this timeline
Invest
Leadership
Steve Willey
CEO, President, Director
Tech Entrepreneur with multiple successful exits; Former President, MicroVision
Arthur Zhang
Chief Technology Officer
Former Apple Vision Systems Architect; Expert in AR/VR Development
Jay Marsh
Senior VP Engineering (Fractional)
Former VP Engineering at APRI; Mechanical & Systems Design Expert
Vijay Raghavan
CFO, Board Member
Ex-Microsoft Controller; Expert in scaling startup Finances & Administration
Corrinalyn Guyette
VP Strategic Growth & Partnerships
Former T-Mobile Exec driving growth, operational excellence, & transformative customer impact.
Bill Meyers
VP Lens Development
Former VP of Science & Technology, Paragon; Contact Lens Expert
Bambo Sofola
Business Strategy
Partner General Manager of Software Engineering within Microsoft's Devices Group.
Advisory & Board
Peter DeGraziano
OD, FAAO, FIALVS
Low-vision specialist; Functional vision loss and vision rehabilitation
Ilya Volk
OD, Contact Lens Specialist
Contact Lens Optometrist and Regulatory Practitioner.
Isaac Jean-Paul
Brand Ambassador
Paralympic Silver Medalist and World Record Holder.
Avram Miller
Business Advisor
Co-founder of Intel Capital, major player in Silicon Valley venture investing.
Casey Tegreene
Tech Strategist
Named on 1,100+ patents, ex-CTO of MicroVision, IP specialist.
Duco Pasmooij
Supply Chain Consultant
Former VP at Apple Inc. 25+ years of experience in Supply Chain and Operations Management
Mark Bullimore
OD, PhD Vision Science
Contributed to FDA approval of CooperVision MiSight, Alcon iLux, Paragon CRT & Zeiss IOLMaster.
Dana Kindberg
OD, Healthcare Entrepreneur
Founder of Urban Eyes; integrates design & advanced diagnostics to elevate patient-centered eye care.
Innovega has a mission to become a worldwide leader in the global transition to wearable vision tech
I'm Ready to Invest
Frequently Asked Questions
I'm Ready to Invest
1
Who can benefit from Innovega's smart glasses?
Our technology is designed to restore functional vision and independence for the 295 million people worldwide with moderate to severe visual impairments, including those who are legally blind, often due to conditions like age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, Stargardt disease, and ocular albinism. Beyond medical use, the platform has applications for defense (enhanced situational awareness), public safety, sports, gaming, and enterprise, making it a versatile solution for both accessibility and broader AR needs.
2
When are you doing in-person demonstrations?
We are actively conducting in-person demonstrations at our San Diego lab, in partnership with optometry professionals. These sessions showcase the Gen I prototypes' ability to restore functional vision in real time, with participant feedback highlighting improved clarity, face recognition, and navigation. As we approach launch, we plan to expand demos for low vision applicants, and early adopters.


Demonstrations describe prototype testing and evaluation and do not imply guaranteed or permanent results.
3
What is your plan for going into commercial production?
Currently we are finalizing full-function prototypes for the Gen I Founders Series Smart Glasses, building an early reservation list (700+ already), and preparing for scaled manufacturing. Gen I is targeted for launch in 2026, with Gen II (glasses + nano-optic contacts) following in 2027/2028 after Phase III FDA trials.

Reservation figures reflect expressions of interest and do not represent completed sales or binding purchase commitments.
4
Who are your current business partners and contracts?
Most of our strategic relationships and development contracts are under confidentiality agreements. That said, we have secured partnerships with industry leaders like Tencent (early lead investor), Vuzix (AR/smart glasses collaborator), Vispero (accessibility partner), and U.S. government agencies (including DARPA/DoD for $6M+ in non-dilutive contracts). We have also executed joint development agreements with trade partners. As soon as we are able to make public announcements, we will share this with insider investors first.
5
What kind of exit strategy do you have planned?
Our primary focus is on growing the company and achieving commercialization of Gen I and Gen II products. Potential future exit strategies could include a public offering (IPO), merger, or acquisition by a larger player in vision care, wearables, or AR. We will share any information that can be made public with insider investors first. While we are under certain confidentiality agreements and SEC regulations that prohibit disclosing certain details herein, please refer to our SEC filings on EDGAR for more information.
6
How do these compare to other smart glasses on the market?
Innovega's Gen I Smart Glasses are purpose-built for people with moderate to severe low vision, delivering clinically validated functional vision restoration, with a transparent see-through display, 45° field of view, HD μOLED quality, and ultra-lightweight design (<90g) for true all-day, stigma-free wear. Our nano-optic technology enables natural, full-field viewing without blocking the real world, ideal for reading, face recognition, navigation, and independence.
In comparison:

Low-vision specific competitors (e.g., eSight Go, Eyedaptic Eye 5) are often bulky, awkward-looking, with blocked displays that limit mobility and feel isolating, restricting them to short-term use rather than everyday empowerment.

Mainstream smart glasses (e.g., Meta Ray-Ban series, including Display models) are stylish and lightweight, but they lack the specialized optics, field of view, and magnification needed to enhance vision capabilities. They're great for general consumers but not designed or validated for restoring sight in legally blind users. Our system bridges medical restoration with future AR potential.


See our investor deck for a detailed performance comparison chart, including features like weight, wearability, display type, and field of view.
7
Why does Innovega welcome retail investors?
Innovega welcomes retail investors because we believe in democratizing access to transformative technology that addresses a massive unmet need for the visually impaired community. By opening this opportunity early, we’re not only raising capital from a diverse group but also building a strong community of supporters genuinely invested in our mission to restore independence and quality of life. This aligns with our values of accessibility and inclusion.
8
Is there a public market for Innovega’s shares?
We are currently a private company with no public exchange to trade shares. As a result, investments in this offering are illiquid, and investors should be prepared to hold their shares for an extended period. We will continue to include any new details that can be shared regarding the company’s long-term growth and corporate development through email updates to investors.

Functional vision outcomes vary by individual and condition and reflect performance during demonstrations or testing. Statements regarding product launches, manufacturing scale, regulatory progress, or future availability reflect current targets and expectations and are subject to change. Competitive comparisons are based on publicly available information and internal evaluations and are provided for general informational purposes.
Innovega Terms
Overview
Price Per Share
$3.00
Valuation
$67.85M
Deadline1
Mar. 30, 2026 at 11:59 PM PT
Funding Goal2
$10K - $5M
Breakdown
Min Investment
$498.00
Offering Type
Equity
Max Investment
$4,999,998.00
Shares Offered
Common Stock
Min Number of Shares Offered
3,333
Max Number of Shares Offered
1,666,666
*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.
Exclusive Investor Perks
Venture Club
Venture Club Members 
earn 10% bonus shares on top of this and all eligible investments for an entire year. Not a member? Sign up at checkout ($275/year).
Loyalty Bonus: 10% bonus shares for previous investors and select loyal supporters.

*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.

Crowdfunding investments made through a self-directed IRA cannot receive non-bonus share perks due to tax laws. The Internal Revenue Service (IRS) prohibits self-dealing transactions in which the investor receives an immediate, personal financial gain on investments owned by their retirement account. As a result, an investor must refuse those non-bonus share perks because they would be receiving a benefit from their IRA account.

The 10% StartEngine Venture Club Bonus

Innovega Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Venture Club.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $3.00 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $300. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and the time of offering elapsed (if any). Eligible investors will also receive the Venture Club Bonus, and the Loyalty Bonus in addition to the aforementioned bonus.Multiple investments in an offering cannot be combined to qualify for a larger campaign perk.

Time-Based Perks
Early Bird 1
$1,000+
Invest $1,000+ within the first 2 weeks and receive 7% bonus shares
Invest
Early Bird 2
$5,000+
Invest $5,000+ within the first 2 weeks and receive 10% bonus shares
Invest
Early Bird 3
$10,000+
Invest $10,000+ within the first 2 weeks and receive 13% bonus shares
Invest
Early Bird 4
$20,000+
Invest $20,000+ within the first 2 weeks and receive 15% bonus shares
Invest
Early Bird 5
$30,000+
Invest $30,000+ within the first 2 weeks and receive 30% bonus shares
Invest
Early Bird 6
$50,000+
Invest $50,000+ within the first 2 weeks and receive 35% bonus shares
Invest
Amount-Based Perks
Tier 1
$1,000+
Invest $1,000+ and receive 5% bonus shares
Invest
Tier 2
$5,000+
Invest $5,000+ and receive 7% bonus shares
Invest
Tier 3
$10,000+
Invest $10,000+ and receive 10% bonus shares
Invest
Tier 4
$20,000+
Invest $20,000+ and receive 13% bonus shares
Invest
Tier 5
$30,000+
Invest $30,000+ and receive 20% bonus shares
Invest
Tier 6
$50,000+
Invest $50,000+ and receive 25% bonus shares
Invest
Venture Club
Venture Club Members 
earn 10% bonus shares on top of this and all eligible investments for an entire year. Not a member? Sign up at checkout ($275/year).
Early Bird 1
$1,000+
Invest $1,000+ within the first 2 weeks and receive 7% bonus shares
Invest
Early Bird 2
$5,000+
Invest $5,000+ within the first 2 weeks and receive 10% bonus shares
Invest
Early Bird 3
$10,000+
Invest $10,000+ within the first 2 weeks and receive 13% bonus shares
Invest
Early Bird 4
$20,000+
Invest $20,000+ within the first 2 weeks and receive 15% bonus shares
Invest
Early Bird 5
$30,000+
Invest $30,000+ within the first 2 weeks and receive 30% bonus shares
Invest
Early Bird 6
$50,000+
Invest $50,000+ within the first 2 weeks and receive 35% bonus shares
Invest
Tier 1
$1,000+
Invest $1,000+ and receive 5% bonus shares
Invest
Tier 2
$5,000+
Invest $5,000+ and receive 7% bonus shares
Invest
Tier 3
$10,000+
Invest $10,000+ and receive 10% bonus shares
Invest
Tier 4
$20,000+
Invest $20,000+ and receive 13% bonus shares
Invest
Tier 5
$30,000+
Invest $30,000+ and receive 20% bonus shares
Invest
Tier 6
$50,000+
Invest $50,000+ and receive 25% bonus shares
Invest
Loyalty Bonus: 10% bonus shares for previous investors and select loyal supporters.
‍
*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.
The 10% StartEngine Venture Club Bonus

Innovega Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Venture Club.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $3.00 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $300. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and the time of offering elapsed (if any). Eligible investors will also receive the Venture Club Bonus, and the Loyalty Bonus in addition to the aforementioned bonus.Multiple investments in an offering cannot be combined to qualify for a larger campaign perk.

Join the Discussion

Please check your email for the One Time Password. Didn't Receive an email? click Here
LEGAL DISCLAIMER
This Reg CF offering is made available through StartEngine Primary LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
Invest
© 2025 Innovega® All Rights Reserved Privacy Policy | Terms & Conditions